IP Group, CIC and Johnson & Johnson have returned for a $52.2m series B round in Inivata, a spinout of Cancer Research UK and University of Cambridge.
Inivata, a UK-based oncology genomics technology spinout, closed a £39.8m ($52.2m) series B round today backed by Cambridge Innovation Capital (CIC), the patient capital affiliate of University of Cambridge.
Commercialisation firm IP Group also took part, as did Johnson & Johnson Innovation – JJDC, the healthcare group’s corporate venturing subsidiary, and Woodford Patient Capital Trust, operated by fund manager Woodford Investment Management.
RT Ventures also contributed to the round, which was oversubscribed and raised over two tranches. The first close was achieved in August 2018, though further details could not be ascertained.
Founded in 2014, Inivata has developed a blood test that extracts essential genomic information to detect cancer mutations and indicate an individual’s response to a therapy, helping clinicians make informed choices in the treatment of their patients.
The lead product, InVisionFirst-Lung is aimed at patients suffering from non-small-cell lung carcinoma and is commercially available. Inivata…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
